The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Weak to moderate cytoplasmic staining in malignant tissues. Strongest staining in malignant melanomas and gliomas, renal, pancreatic and liver cancers. Malignant lymphomas were negative.
Most malignant cells displayed moderate cytoplasmic positivity often combined with nuclear immunoreactivity. Several testicular cancers and malignant gliomas exhibited strong cytoplasmic positivity.
Validation
Two (or more) antibodies yielding similar or partly similar staining patterns and there is no available gene/protein characterization data
Two (or more) antibodies yielding similar or partly similar staining patterns and there is no available gene/protein characterization data
